Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novacor upgrade

This article was originally published in The Gray Sheet

Executive Summary

WorldHeart will begin shipping an upgraded version of the left-ventricular assist device in the U.S. and Canada by the end of March, the company notes in a Jan. 7 release announcing FDA approval of the enhancements. Already approved in Canada and Europe, improvements include quieter pump operation, a smaller, longer-lasting battery and a smaller, quieter battery charger, according to the firm. Novacor is FDA-approved as a bridge to transplant, and will be the subject of a 250 to 300-patient destination therapy trial this year (1"The Gray Sheet" Nov. 10, 2003, p. 39)...
Advertisement

Related Content

WorldHeart Changes LVAD Development Plan, Cites Medicare Trial Coverage
WorldHeart Changes LVAD Development Plan, Cites Medicare Trial Coverage
Advertisement
UsernamePublicRestriction

Register

MT019593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel